Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.90 |
| ▸ | DRD3 | P35462 | 8/20 | 0.90 |
| ▸ | DRD4 | P21917 | 3/20 | 0.90 |
| ▸ | DRD1 | P21728 | 3/20 | 0.90 |
| ▸ | HTR1A | P08908 | 1/20 | 0.90 |
| ▸ | DRD5 | P21918 | 1/20 | 0.90 |
| ▸ | HTR7 | P34969 | 1/20 | 0.90 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21262950 | 1.00 | DRD2 (0.90) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL17446178 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL279021 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL29420186 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL5705486 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL30201073 | 0.94 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL8891873 | 0.89 | HTR1A (0.90) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL29062563 | 0.88 | DRD2 (0.88) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL24314254 | 0.87 | DRD2 (0.91) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL11199129 | 0.86 | DRD2 (0.84) | DRD2DRD3DRD4DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022089408-A1 | TETRAHYDRONAPHTHALENE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| US-10314837-B2 | Subcutaneous delivery of poly(oxazoline) polymer conjugates | SERINA THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314837-B2 | Subcutaneous delivery of poly(oxazoline) polymer conjugates | OXA1L, PAM, JMJD7 | DRD2 3087/4885DRD3 3301/4885DRD4 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.